Lana Pine

The rituximab biosimilar rixathon was linked to the the lowest average annual cost per patient across 6 indications among all biosimilars.

The predominant themes observed were the presence of a specific trigger (stressful event) for fibromyalgia symptoms, fulfilling expected gender roles, a lack of support from family members, and abuse.

Combination methotrexate plus bDMARDs, bsDMARDs, and tsDMARDs provided .009 to .33 quality-adjusted life years gained with additional costs of $15,957 to $60,722 when compared with standard of care.

Themes regarding improvement experience, developing strategies for better health, and contextual factors supporting improvement were reported during the interview analysis.

All primary endpoints evaluating pharmacokinetics were achieved and immunogenicity and safety were comparable across treatment arms.

Pain intensity, quality of life, and depression were significantly improved in a cohort of patients with fibromyalgia treated with THC.

The yoga-based, mind-body intervention was effective for most patients with chronic pain, with the largest effects demonstrated in areas of pain self-efficacy, pain intensity, quality of life, and most severe perceived pain.

Results found all clinical and patient-reported responses were statistically better with upadacitinib plus methotrexate compared with adalimumab plus methotrexate, although both treatments were effective.

Guselkumab was able to provide minimal disease activity improvements from baseline through week 48 in adult patients with psoriatic arthritis.

In this episode of Relatable Rheumatology, experts discuss a critically important topic for patients with rheumatoid arthritis: bloodwork and laboratory tests.

After rituximab treatment, patients experienced a reduction of symptoms, corticosteroid administration, and median corticosteroid dose from baseline.

Patients with unrestful sleep had significantly reduced health-related quality of life and significantly more depressive symptoms.

The risk of ischemia heart disease was significantly higher in the SLE cohort when compared with controls, with risks peaking between the 6th and 9th year post-diagnosis.

The rheumatology month in review highlights a program developed by Janssen to support health equity, the increased risks pregnant women with rheumatic diseases face, and trends in fibromyalgia management.

The biosimilars month in review highlights infliximab biosimilars data presented at Digestive Disease Week (DDW) 2023, California’s proposed plan to produce and market biosimilar insulin at production-equivalent prices, and new FDA approvals.

While most patients were interested in an online wellness program for managing their psoriatic arthritis, barriers, such as cost and fatigue, hindered their initiation of lifestyle adaptations.

Patients in the land- and water-based exercise intervention groups demonstrated greater improvements in fatigue when compared with controls.

More than 90% of respondents reported being “somewhat likely” or “very likely” to speak with an online coach ≥2 per week or spend 1 – 2 hours per week learning about lifestyle behaviors if given the opportunity.

The study stresses the need for better communication with patients and the impact of stress on both the rheumatic disease and mental health.

Results emphasized the challenges faced in accessing care and the impact on mental health for patients with rheumatic diseases.

A modification of DAS28 was shown to more accurately represent disease activity in patients with rheumatoid arthritis and concomitant fibromyalgia.

Patients with rheumatoid arthritis and high disease activity were more likely to be diagnosed with depression and fibromyalgia when compared with those in remission.

After 12 weeks of treatment, the median sUA levels of patients with gout were reduced from 8.6 mg/dL to 3.6 mg/dL in the AR882 75 mg cohort and 5.0 mg/dL in the AR882 50 mg group.

Results of the SELECT-AXIS 2 study supported the efficacy and safety profile of upadacitinib in patients with active ankylosing spondylitis who had an inadequate response to biologic DMARD therapy.

Over a 3-year period, patients treated with upadacitinib reported greater disease improvements and a greater mean change from baseline when compared with those receiving adalimumab.

Response rates in the DISSOLVE I and DISSOLVE II high-dose and low-dose groups receiving SEL-212 were significantly different from the placebo group.

Patients receiving 6MP prophylaxis experienced significantly reduced incidence of arthromyalgia and Health Assessment Questionnaire worsening of 22% or increase of .25.

In patients with systemic lupus erythematosus receiving rituximab and belimumab, Black and Indo-Asian patients were less likely to obtain major clinical response.

Within the reactive care gout conversations, “pain” and “swelling” were significantly more likely to be mentioned when compared with proactive care conversations.

Between 2000 and 2019, age-standardized incidence rates of autoimmune diseases increased by 4%.